139 related articles for article (PubMed ID: 21325980)
1. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation.
Jang KW; Lee JE; Kim SY; Kang MW; Na MH; Lee CS; Song KS; Lim SP
J Thorac Oncol; 2011 Apr; 6(4):679-87. PubMed ID: 21325980
[TBL] [Abstract][Full Text] [Related]
2. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
[TBL] [Abstract][Full Text] [Related]
3. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
4. The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation.
Chung C; Yoo G; Kim T; Lee D; Lee CS; Cha HR; Park YH; Moon JY; Jung SS; Kim JO; Lee JC; Kim SY; Park HS; Park M; Park DI; Lim DS; Jang KW; Lee JE
Biochem Biophys Res Commun; 2016 Oct; 479(2):152-158. PubMed ID: 27475501
[TBL] [Abstract][Full Text] [Related]
5. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
To C; Seiden I; Liu N; Wigle D; Tsao MS
Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
[TBL] [Abstract][Full Text] [Related]
7. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2.
Kim DG; Lee JY; Lee JH; Cho HY; Kang BS; Jang SY; Kim MH; Guo M; Han JM; Kim SJ; Kim S
Cancer Res; 2016 Jun; 76(11):3422-36. PubMed ID: 27197155
[TBL] [Abstract][Full Text] [Related]
9. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
10. The Antitumor Effect of C-terminus of Hsp70-Interacting Protein via Degradation of c-Met in Small Cell Lung Cancer.
Cho SH; Kim JI; Kim HS; Park SD; Jang KW
Korean J Thorac Cardiovasc Surg; 2017 Jun; 50(3):153-162. PubMed ID: 28593150
[TBL] [Abstract][Full Text] [Related]
11. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
12. GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug.
Kao SH; Wang WL; Chen CY; Chang YL; Wu YY; Wang YT; Wang SP; Nesvizhskii AI; Chen YJ; Hong TM; Yang PC
Oncogene; 2014 Jun; 33(24):3172-82. PubMed ID: 23851495
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
[TBL] [Abstract][Full Text] [Related]
14. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
Fan M; Park A; Nephew KP
Mol Endocrinol; 2005 Dec; 19(12):2901-14. PubMed ID: 16037132
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
17. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
19. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.
Cao L; Wang F; Li S; Wang X; Huang D; Jiang R
Cancer Lett; 2019 Mar; 444():116-126. PubMed ID: 30583073
[TBL] [Abstract][Full Text] [Related]
20. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
Hou J; Deng Q; Zhou J; Zou J; Zhang Y; Tan P; Zhang W; Cui H
Oncogene; 2017 Feb; 36(8):1134-1144. PubMed ID: 27546621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
